Page last updated: 2024-11-02

pirenzepine and Cardiomyopathy, Congestive

pirenzepine has been researched along with Cardiomyopathy, Congestive in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Matsui, S1
Fu, ML1
Hayase, M1
Katsuda, S1
Yamaguchi, N1
Teraoka, K1
Kurihara, T1
Takekoshi, N1

Other Studies

1 other study available for pirenzepine and Cardiomyopathy, Congestive

ArticleYear
Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor.
    Journal of cardiovascular pharmacology, 2001, Volume: 38 Suppl 1

    Topics: Animals; Anti-Arrhythmia Agents; Autoimmune Diseases; Blood Pressure; Body Weight; Cardiomyopathy, D

2001
chemdatabank.com